Cialis Phase III study in Benign Prostatic Hyperplasia is reported in Jo.Sexual Medicine

A pivotal Phase III study of Cialis (tadalafil) tablets 5 mg from Eli Lilly and Company for once daily use met its co-primary endpoints, significantly improving measures of both erectile dysfunction (ED) and signs and symptoms of benign prostatic hyperplasia (BPH) in men with both conditions. The study is available online in The Journal of Sexual Medicine . It is one of three efficacy and safety studies included in the supplemental new drug application Lilly submitted to the FDA last year seeking approval for Cialis in the treatment of the signs and symptoms of BPH and the treatment of both ED and the signs and symptoms of BPH (ED+BPH). This approval has now been granted.